On Oct. 28, 2021, Pfizer and BioNTech announced that the U.S. government had purchased 50 million more doses of the companies’ COVID-19 vaccine. The U.S. will receive these additional doses to continue to support preparedness for pediatric vaccinations, including securing vaccines for children under 5 years of age, should they receive regulatory authorization. The companies expected to deliver all these doses by Apr. 30, 2022.